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ntius HoAbstract Background: Sequential chemotherapy and individualised accelerated radiotherapy
(INDAR) has been shown to be effective in non-small cell lung cancer (NSCLC), allowing
delivering of high biological doses. We therefore performed a phase II trial (clinicaltrials.gov;
NCT00572325) investigating the same strategy in concurrent chemo-radiation in stage III
NSCLC.
Methods: 137 stage III patients fit for concurrent chemo-radiation (PS 0-2; FEV1 and DLCO
P30%) were included from April 2006 till December 2009. An individualised prescribed dose
based on normal tissue dose constraints was applied: mean lung dose (MLD) 19 Gy, spinal
cord 54 Gy, brachial plexus 66 Gy, central structures 74 Gy. A total dose between 51 and
69 Gy was delivered in 1.5 Gy BID up to 45 Gy, followed by 2 Gy QD. Radiotherapy was
started at the 2nd or 3rd course of chemotherapy. Primary end-point was overall survivallsevier Ltd. All rights reserved.
14
ting of ASTRO 2010, San Diego and the Annual Meeting of the World Conference on Lung Cancer 2011,
plete report of the study.
4 55 666; fax: +31 88 44 55 667.
@maastro.nl (A.van Baardwijk).
spital, Roermond, The Netherlands.
2340 A.van Baardwijk et al. / European Journal of Cancer 48 (2012) 2339–2346(OS) and secondary end-point toxicity common terminology criteria for adverse events v3.0
(CTCAEv3.0).
Findings: The median tumour volume was 76.4 ± 94.1 cc; 49.6% of patients had N2 and 32.1%
N3 disease. The median dose was 65.0 ± 6.0 Gy delivered in 35 ± 5.7 days. Six patients (4.4%)
did not complete radiotherapy. With a median follow-up of 30.9 months, the median OS was
25.0 months (2-year OS 52.4%). Severe acute toxicity (PG3, 35.8%) consisted mainly of G3
dysphagia during radiotherapy (25.5%). Severe late toxicity (PG3) was observed in 10
patients (7.3%).
Interpretation: INDAR in concurrent chemo-radiation based on normal tissue constraints is
feasible, even in patients with large tumour volumes and multi-level N2–3 disease, with accept-
able severe late toxicity and promising 2-year survival.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
Non-small cell lung cancer (NSCLC) is one of the
most frequently diagnosed cancers and the leading cause
of cancer death.1 Stage III disease represents about one
third of all NSCLC with concurrent chemo-radiation as
treatment of choice2 and only for a selected group che-
motherapy and surgery. As local tumour control
remains low, strategies for improvement have been
investigated including increasing radiation dose, acceler-
ated hyperfractionated radiation and targeted agents.3–8
Increasing the dose is challenging due to the tolerance of
normal tissues, e.g. lung and spinal cord. In most dose-
escalation trials, a certain threshold for organs at risk
has been implemented together with a fixed dose (e.g.
74 Gy). As a consequence, the dose will be dependent
on tumour volume; only patients with relatively small
volume disease being capable to receive a high dose.
In order to deliver the highest possible radiation dose
to every individual patient we developed a strategy in
which the radiation fields were kept as small as possible
with selective nodal irradiation based on Fluordeoxyglu-
cose - Positron Emission Tomography - Computer
Tomography (FDG-PET-CT) scans9 and accelerated
radiotherapy in order to increase the biological effective-
ness.10,11 As such, patients receive the highest possible
biological radiation dose with the best therapeutic ratio.
We previously demonstrated that individualised acceler-
ated radiotherapy (INDAR) with radiotherapy alone or
sequential chemo-radiation is feasible with acceptable
toxicity and promising results.12
Another strategy to improve local control and overall
survival (OS) is concurrent chemo-radiation.2,5 A meta-
analysis based study showed a significant benefit in OS
for concurrent chemo-radiation compared to sequential
chemo-radiation, but at the expense of more transient
oesophageal toxicity.2 Most patients received a dose of
60 Gy in 30 fractions in 6 weeks in this meta-analysis,
at present considered to be the standard scheme in con-
current chemo-radiation. However, dose escalation in
concurrent chemo-radiation seems feasible,3,13 and indi-
rect evidence suggests that radiation dose escalation mayalso improve survival in the context of concurrent
chemo-radiation.14
We hypothesised that combining concurrent chemo-
radiation with INDAR based on normal tissue con-
straints could further improve survival in stage III
NSCLC. Here, we report the mature results of a large
prospective phase II study applying this INDAR
approach in concurrent chemo-radiation.
2. Methods
2.1. Patients
From 1st April 2006 until 31st December 2009
patients eligible for concurrent chemo-radiation were
entered in this prospective study conducted at MAAS-
TRO clinic. Included were patients with stage III, except
pleural effusion (Union for International Cancer Con-
trol, TNM 6th edition),15 histological/cytological con-
firmed NSCLC, no prior thoracic radiation and a
work-up according to national guidelines,16 including a
staging FDG-PET-CT scan and a Magnetic Resonance
Imaging (MRI) or a contrast-enhanced CT scan of the
brain. A World Health Organisation Performance Sta-
tus (WHO-PS) of 0–2 was required and a weight loss
of less than 10% in 6 months. All patients had to have
a moderate to good lung function FEV1 (Forced Expira-
tory Volume in the first second) P 30% and DLCO
(Carbon Monoxide Diffuse Capacity) P 30% of pre-
dicted value.
2.2. Study design and procedures
Chemotherapy consisted of 1–2 cycles of carbo-
platin–gemcitabine (carboplatin AUC 5, gemcitabine
1250 mg/m2), followed by concurrent cisplatin–vinorel-
bine (cisplatin 40–50 mg/m2, vinorelbine 15–20 mg/m2)
or concurrent cisplatin–etoposide every 3 weeks (cis-
platin 75–80 mg/m2 day 1, etoposide 100 mg/m2 day
1–3) with radiotherapy. The regimen depended on the
referring hospital. Dose-reduction was applied accord-
ing to guidelines and in case of renal failure cisplatin
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planning was performed during the first cycle of chemo-
therapy and radiotherapy was intended to start at the
first day of the second cycle of chemotherapy. The study
was approved by the institutional review board and reg-
istered on clinicaltrials.gov (NCT00572325). Informed
consent was obtained from all patients prior to
radiotherapy.2.2.1. Radiotherapy treatment planning
A PET-CT scan and a 4D-CT scan was performed
before start of radiation (Biograph, Siemens) and delin-
eation was based on fused PET-CT images.9,11 The total
gross tumour volume (GTV) consisted of the primary
tumour (GTV-1; CT based volume based on the midven-
tilation scan) and GTV-2.9 Only the initial PET-positive
lymph nodal areas, based on the diagnostic PET-CT
before any treatment, and nodes proven to be malignant
were included in GTV-2. No elective mediastinal irradi-
ation was carried out, according to European Organisa-
tion for Research and Treatment of Cancer (EORTC)
guidelines.9 For the Clinical Target Volume (CTV-1
and CTV-2) a margin of 5 mm around GTV was used.
The Planning Target Volume (PTV) was created by add-
ing a 10 mm margin to CTV-1 and a 5 mm margin to
CTV-2. For the calculation of the mean lung dose
(MLD), the volume of both lungs minus GTV was con-
sidered.9 The spinal cord was drawn at the inner margin
of the bony spinal canal.
A 3D conformal treatment plan was calculated (XiO,
CMS, Inc.) according to the International Commission
on Radiation Units and Measurements (ICRU) Report
5017 using a Fast Fourier Transform convolution-super-
position algorithm taking into account inhomogeneity
corrections. Patients were irradiated with a linear accel-
erator (Siemens Oncor, Siemens Medical Solutions,
Concord, CA). All patients were treated with 6 MV or
10 MV photon beams.9,18 Treatment verification was
performed using EPID measurements.2.2.2. Treatment description
For all patients enrolled, the prescribed dose was indi-
vidually escalated until a dose-limiting normal tissue con-
straint was reached: a maximal MLD of 19.0 ± 1.0 Gy, a
maximal spinal cord dose of 54.0 ± 0.5 Gy, and a maxi-
mal plexus brachialis dose of 66 Gy was applied.19–22
Since most tumours were centrally located and/or had
involved mediastinal nodes the maximal allowed dose
was 69 Gy to respect a dose inhomogeneity with a maxi-
mum of 107% to great vessels or main bronchi of
74 Gy.22,23 No specific oesophageal dose constraint was
used, except a Dmax of 74 Gy.24 The dose was delivered
in an accelerated scheme: 1.5 Gy fractions twice daily up
to 45 Gy with an interfraction interval of at least 8-hours,
followed by once daily fractions of 2 Gy based on the
ESPATÜ phase III trial scheme.13 The biologicalequivalent dose for tumour in 2 Gy fractions was calcu-
lated using the linear quadratic model25–27 and corrected
for overall treatment time (EQD2,T).
102.4. End-points
Primary end-point was OS, secondary end-point pro-
gression free survival (PFS) and toxicity. Patients were
seen before start of radiotherapy, weekly during treat-
ment, 1 month after radiotherapy and every 3–6 months
for the first 2 years and yearly afterwards. Additional
toxicity information was collected by validated ques-
tionnaires from 2009 on. Acute (<90 days from start
of radiotherapy) and late (P90 days from start of radio-
therapy) toxicity was scored according to Common Ter-
minology Criteria for Adverse Events v3.0 (CTCAE).
Clinical tests (imaging) were used to determine local
progression or distant failure. If progression was sus-
pected a (PET-) CT was performed and if necessary a
biopsy was considered. Survival status was evaluated
in February 2011 using the GBA system, a decentralised
population registration system containing information
about all inhabitants of The Netherlands.3. Statistical analysis
Assuming an increase in 2-year OS of 10% compared
to a classical concurrent chemo-radiation schedule to be
successful, a number of 145 patients was calculated to
provide sufficient statistical power (power = 0.8,
alpha = 0.05, p0 = 35%, p1 = 45%). Due to the clinical
implementation of Intensity-Modulated Radiation Ther-
apy (IMRT) the inclusion of patients was closed at 137
patients, since IMRT results in other dose distributions
than 3DCRT. The SPSS software (SPSS for Windows,
Chicago, IL) was used for statistical analysis. OS was
defined as time from diagnosis till death using the Kap-
lan–Meier method (log-rank test for comparison of sur-
vival). PFS was defined as the time from diagnosis until
first clinical event (local or distant progression or death
from any cause). Median survival rates are expressed
with their 95% confidence intervals (CI). The Cox pro-
portional hazards model was used for multivariate anal-
ysis testing the following variables: primary tumour,
nodal and total gross tumour volume (GTV-1, GTV-2,
total GTV), EQD2,T, Total tumour (TTD), stage,
WHO-PS, gender, age, histology and type of chemother-
apy. Crude incidences of pulmonary complaints (cough
and dyspnoea), oesophageal dysphagia were calculated.4. Findings
4.1. Patient and treatment characteristics
Between 1st April 2006 and 31st December 2009 137
patients, 88 males and 49 females with a median age of
Table 1














Squamous cell carcinoma 40 (29.2)
Adenocarcinoma 22 (16.1)






Type of concurrent chemotherapy
Cisplatin–etoposide 94 (68.6)
Cisplatin–vinorelbine 39 (28.5)
Carboplatin based 4 (2.9)
Gross tumour volume




Median (range) in Gy 65.0 (51–69)
EQD2,T corrected for proliferation
Median (range) in Gy 53.9 (43.1–63.1)
MLD
Median (range) in Gy 16.3 (4.4–21.0)
OTT
Median (range) in days 35 (18–48)
GTV = total gross tumour volume, TTD = total tumour dose,
EQD2,T = equivalent dose in 2 Gy fractions corrected for prolifera-
tion, MLD = mean lung dose, OTT = overall treatment time and
WHO-PS = World Health Organisation Performance Score.
2342 A.van Baardwijk et al. / European Journal of Cancer 48 (2012) 2339–234663.2 ± 9.0 years (range: 40–80 years) were enrolled.
Patient and tumour characteristics are presented inTable1.
Stage distribution was as following: IIB 0.7% (n = 1), IIIA
36.5% (n = 50), IIIB 62.8% (n = 86), including 8 patients
(5.8%) with recurrent (stage III) disease. Stage IIIB
(n = 86) consisted of 42 patients with T4N0-2 disease, 36
patients with T0-3N3 disease and 8 patients with T4N3 dis-
ease. Concurrent chemotherapy consisted in 94 patients
(68.6%) of cisplatin–etoposide, in 39 patients (28.5%) of
cisplatin–vinorelbine and in 4 patients carboplatin based
(2.9%). The median interval between the 1st cycle of che-
motherapy and start of radiotherapy was 22 ± 15.0 days
(0–85 days). The median total GTV was 76.4 ± 94.1 cc
(3.7–518.9 cc). Only 22 patients (16.1%) had N0 disease,
while 3 (2.7%), 68 (49.6%) and 44 patients (32.1%) hadN1, N2 or N3 disease respectively. The median dose for
the total group of patients was 65.0 ± 6.0 Gy (51–69 Gy)
delivered in a median OTT of 35 ± 5.7 days (18–48 days).
This equals a median EQD2,T of 53.9 ± 3.9 Gy (range
43.1–63.1 Gy), which equals a dose of 72 Gy delivered in
36 once-daily fractions of 2 Gy. Five patients did not com-
plete their radiation: 2 patients due to intercurrent disease
(cerebrovascular accident, myocardial infarction) and 3
patients wished to stop since the schedule was too exhaust-
ing. The median MLD was 16.3 ± 3.5 Gy (range 4.4–
21.0 Gy) and the dose to the spinal cord 49.2 ± 10.2 Gy
(range 14.1–56.9 Gy). In 43 patients (31.4%) the MLD
was dose-limiting. In 10 patients (7.3%) a protocol viola-
tion was encountered; 1 patient with stage IIB with a large
tumour (315.1 cc) was included, and in 9 patients (6.6%)
the dose constraints were not fulfilled: 2.2% an
MLD > 20 Gy (resp. 20.2, 20.4 and 21.0 Gy) and 4.4% a
maximal dose to the spinal cord > 54.5 Gy (resp. 54.8,
55.0, 55.3, 56.4, 56.4 and 56.9 Gy).4.2. Survival
The median follow-up time was 30.9 months (95%CI
28.5–33.5 months). At the time of analysis 76 patients
(55.5%) had died. The median OS was 25.0 months
(95%CI 19.8–30.3 months) with a 1-year OS of 72.2%
and a 2-year OS of 52.4% (Fig. 1a). For the different
stages the median OS was as following: stage IIIA
24.2 months (95%CI 15.5–32.9 months) and stage
IIIB 29.1 months (95%CI 18.1–40.1 months; p = 0.51;
Fig. 1b). The median PFS was 14.0 months (95%CI
9.5–18.5 months) with a 1-year PFS of 54.7% and a 2-
year PFS of 35.5% (Fig. 1c). Eighty patients (58.4%)
showed recurrent disease: 5.1% (n = 7) an isolated local
recurrence, 4.4% (n = 6) an isolated regional recurrence,
5.1% (n = 7) a combined local and regional recurrence
and 27.0% (n = 37) distant metastases only. Out of
these 37 patients, 21 (56.8%) had cerebral metastases
as first site of progression. In another 16.8% (n = 23)
local-regional progression was simultaneously (within
1 month) detected with distant metastases.4.3. Uni- and multi-variate analysis survival
On univariate analysis, OS was better with a WHO-PS
of 0 (p = 0.009), smaller nodal volume (GTV-2;
p = 0.015) and a higher EQD2,T (p = 0.037). All other fac-
tors were not correlated with OS (Table 2). On multivar-
iate analysis a favourable WHO-PS (p = 0.006), smaller
nodal volume (GTV-2; p = 0.022) and a higher EQD2,T
(p = 0.044) remained independent factors for a better OS.4.4. Toxicity
Toxicity is depicted in Fig. 2. Severe acute toxicity




Fig. 1. Actuarial Overall Survival (OS) for total group of patients (a), for stages IIIA and IIIB (b), and the actuarial Progression Free Survival
(PFS) (c) in months for the total group of patients.
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(G1:28.5%, G2:37.2%), while G3 dysphagia during
radiotherapy was observed in 25.5% (n = 35). Severe pul-
monary complaints were less frequent: G3 and G4 dysp-
noea were observed in 2.9% and 0.7% respectively and
G3 cough in 8.0% of patients. One month after radio-
therapy G3 dysphagia was observed in only 9 patients
(6.6%).
In total 6 patients (4.4%) died within 3 months after
end of radiotherapy; two due to not otherwise defined
pulmonary causes, 1 patient sepsis, 1 patient cardiomy-
opathy, 1 patient of an abdominal aorta aneurysm and 1
patient of an unknown cause at home.
For severe late toxicity (PG3; P90 days post-radio-
therapy) 131 patients were available. In 10 patients
(7.3%) PG3 toxicity was observed: in 6 patients
(4.6%) this was a G3 dysphagia (in 5 patients due to a
stricture or stenosis and in 1 patient an oesophageal
ulcer). With regard to severe pulmonary toxicity athoracic empyema or fistula was diagnosed in 2 patients
(1.5%) 14 and 6 months after radiotherapy respectively.
One patient had a pneumothorax 3 months after radio-
therapy and developed an empyema subsequently. Three
patients (2.3%) had grade 3 dyspnoea and 1 patient
(0.8%) died of a radiation pneumonitis (grade 5)
3.5 months after radiotherapy. This patient was an 80-
year old male (WHO-PS 1, FEV1 76%, DLCO 77%),
who received a dose of 65 Gy with a MLD of 19.5 Gy.
No case of myelitis was observed.
5. Discussion
Although improvements in treatment of NSCLC
have occurred, the prognosis of locally advanced
NSCLC remains poor. The importance of both total
radiation dose26 and overall treatment time7 have been
demonstrated for local tumour control and sur-
vival.2,7,14 Therefore many groups have tried to increase
Table 2
Univariate and multivariate analysis for overall survival (OS).
Overall survival
Univariate Multivariate
WHO-PS 0 versus WHO-PS P 1 0.009 0.006
GTV-2 < median versus GTV-2 P
median
0.015 0.022
EQD2,T P median versus EQD2,T <
median
0.037 0.044
TTD P median versus TTD < median 0.20 NA




Stage IIIA versus IIIB 0.51 NA
Type of chemotherapy 0.71 NA




Age P median versus age < median 0.85 NA
GTV = total gross tumour volume, TTD = total tumour, EQD2,T =
equivalent dose in 2 Gy fractions corrected for proliferation, and












































































Fig. 2. Percentage of patients with toxicity: maximal scoring according
to Common Terminology Criteria for Adverse Events v3.0 (CTCAE-
criteria v3.0) for baseline, acute toxicity during radiotherapy, 1 month
after radiotherapy and late toxicity (> 90 days) for cough (a), dyspnoea
(b) and oesophagitis (c).
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applying accelerated radiotherapy.6,12,28,29
Another strategy to improve outcome in stage III
NSCLC is concurrent chemo-radiation. A recent meta-
analysis has shown the superiority of concomitant
chemo-radiation over sequential chemo-radiation, 2-
year survival of 35% and 30% respectively.2 In the recent
prospective phase II RTOG-0324 trial in which 93
patients were treated with concurrent carboplatin–pac-
litaxel–cetuximab and radiotherapy to a dose of 63 Gy
in 35 once-daily fractions, the median survival was
22.7 months and the 2-year overall survival 49.3%.8
These results were stated to be better than any previ-
ously reported RTOG study and promising enough to be
the basis of a randomised phase III trial. Without the
addition of cetuximab, our results of a median overall
survival of 25.0 months and a 2-year overall survival rate
of 52.4% in a 137-patients prospective study are in line
with the best results that were achieved in RTOG-0324.
Although the present trial is a phase II non-random-
ised mono-centre trial the selection criteria were not very
stringent: no age criteria were applied (25% of
patients > 70 years, 10.2% > 75 years), patients with
N3 disease (32.1%), including supraclavicular node
involvement and the median tumour volume was rather
large (76 cc). In two phase I trials (RTOG 0117 and
CCTG 0028) and in the randomised phase II CALGB
30105 trial the maximal tolerable dose was 74 Gy in 37
fractions in 7.4 weeks, which is biologically similar to
our schedule. However, due to the dose constraints
together with a fixed tumour dose, it is likely that the
patients included in these studies had smaller tumours.
Unfortunately no data on tumour volumes are available
in the latter studies, although the percentage of IIIB dis-
ease was lower (11%, 23% and 50% respectively) com-
pared to ours (63%). This might be caused by
exclusion of N3 disease in supraclavicular nodes in some
studies. Only 25% of patients included in our study
would have been able to receive a physical dose of
74 Gy, due to MLD or spinal cord constraints.
This series includes a rather large number of large cell
carcinoma (53.2%), due to the historical tendency in
some of the referring hospitals to specify a tumour as
a large cell carcinoma if the histology was not typical
adenocarcinoma or squamous cell carcinoma.
Since all patients included were treated from 2006,
staging included a PET-CT scan and brain imaging.
This might lead to some stage migration and therefore
selection compared to some other studies. Nevertheless,
our results are comparable with these of the aforemen-
tioned trials, even though a lower physical radiation
dose was delivered, be it in a shorter overall treatment
time, thus indirectly supporting the biological activity
of the present schedule.
We observed a 2-year PFS of 39.7% and a 2-year OS
of 52.4%, which is equal to or even better than observed
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the results of 28 patients included in the ESPATÜ study
with potentially resectable locally advanced NSCLC,
who received accelerated chemo-radiation and no resec-
tion, showing a 2-year OS of 50%.13 The meta-analysis
showed a 2-year PFS for concurrent chemo-radiation
of 22.7%. The first event was mainly distant metastasis
(26.7%) and less frequently loco-regional recurrence
(14.6%) or a combination of both (16.8%) in the present
series, compared to 34% distant metastasis and 27%
loco-regional recurrence in the meta-analysis, respec-
tively.2 Although the frequency of distant metastasis
remains high, to the best of our knowledge, further
treatment intensification by adding induction chemo-
therapy or consolidation chemotherapy or targeted
agents to concurrent chemo-radiation has not demon-
strated any survival benefit compared to concurrent
chemo-radiation alone.30,31
Dose prescription was based on normal tissue con-
straints, like MLD. Although no single parameter can
predict lung toxicity, the MLD together with the V20
are the most robust parameters predictive for lung tox-
icity.9 The median radiation dose in this study was
65 Gy, and 27% of patients could receive the maximal
allowed dose (69 Gy). By applying IMRT this number
could probably be increased.32,33 However, it is not
totally clear whether applying IMRT techniques will
lead to similar regional control rates, since the incidental
dose to mediastinal lymph nodes is higher using 3D con-
formal techniques than IMRT. Future studies evaluat-
ing IMRT should answer this question, as well if the
balance of dose-escalation by IMRT and reducing dose
to elective nodes and organs at risk will lead to better
control rates and similar or lower toxicity, like
pneumonitis.
The rate of oesophageal toxicity was rather high
although it consisted mainly of (transient) oesophageal
toxicity (acute G3 dysphagia: 24%). This rate is some-
what higher than mentioned in literature (<20%) and
might be caused by the fact that no specific oesophageal
dose constraints were applied and the accelerated radia-
tion scheme.5 In 4% of patients severe late oesophageal
toxicity was observed, which is in line with literature.3,5
With regard to late pulmonary toxicity we focused on P
grade 3 (3%), since symptoms of pneumonitis, like dysp-
noea and cough might be non-specific and intercurrent
infections or exacerbation of COPD might confound
scoring. We observed one lethal radiation pneumonitis
(0.8%). This compares well with literature.2,3,8
In conclusion, INDAR in concurrent chemo-radia-
tion based on normal tissue constraints is feasible. The
maximal dose of 69 Gy is physically lower than pre-
scribed in other dose-escalation schemes, but biologi-
cally equivalent due to the short overall treatment
time, and is even feasible in patients with large tumour
volumes and multi-level N2-3 disease. It has bothacceptable transient acute toxicity as well as limited
severe late toxicity and shows promising results with a
2 year OS of 52.4%. One of the challenges in the future
is to further individualise treatment of stage III NSCLC,
not only with regard to radiation dose, but also to tailor
systemic therapy to the individual patient to find a bal-
ance between effect and toxicity.Conflict of interest statement
None declared.
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